Journal
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 22, Issue 11, Pages 1915-1925Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2016.07.013
Keywords
Hematopoietic cell transplantation; Busulfan; Precision medicine; Pharmacokinetics; Therapeutic drug monitoring
Categories
Funding
- National Cancer Institute [CM 82963]
Ask authors/readers for more resources
The Practice Guidelines Committee of the American Society of Blood or Marrow Transplantation (ASBMT) sought to develop an evidence-based review about personalizing busulfan-based conditioning. The Committee sought to grade the relevant published studies (June 1, 2008 through March 31, 2016) according to criteria set forth by the Steering Committee for Evidence Based Reviews from ASBMT. Unfortunately, the published literature was too heterogeneous and lacked adequately powered and sufficiently controlled studies for this to be feasible. Despite this observation, the continued interest in this topic led the Practice Guidelines Committee to develop a list of most frequently asked questions (FAQs) regarding personalized busulfan dosing. This Considerations document is a list of these FAQs and their responses, addressing topics of practical relevance to hematopoietic cell transplantation clinicians. (C) 2016 American Society for Blood and Marrow Transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available